Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Op

Ronan J. Kelly, MD, MBA, discusses the significance of the FDA approval of trastuzumab deruxtecan for pretreated, advanced HER2-positive solid tumors.

Related Keywords

Baylor University , Texas , United States , Dallas , American , Ww Caruth Jr , Ronanj Kelly , Trastuzumab Deruxtecan , Baylor Scott White Health , Immunology At Baylor University Medical Center , College Of American Pathologists , Baylor Scott , White Health , North Texas , White Charles , Cancer Center , Baylor University Medical Center , Endowed Chair , American Pathologists , Patients With , Expressing Solid Tumors , Primary Results From , D , Nba , Fda Approval Of Trastuzumab Deruxtecan , Pretreated , Dvanced Her2 Positive Solid Tumors ,